Upon our discovery of a positive correlation between HuR expression and the sensitivity to cell cycle inhibitor drugs, we were reminded of the importance of considering a patient’s individual HuR levels when administering these medications to tumor patients. Here, ELAVL1 is linked to neoplasm.